Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- SENTENCE label "In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers." provenance.
- SENTENCE label "In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers." provenance.
- SENTENCE label "In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.